deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04268823

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Subjects and Investigator Blinded, Placebo Controlled Parallel Group Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: Novartis Pharmaceuticals

Interventions Placebo QBW251
Updated 21 times since 2020 Last updated: Jun 17, 2024 Started: Sep 10, 2020 Primary completion: Sep 13, 2022 Completion: Sep 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

This PHASE2 trial investigates Chronic Obstructive Pulmonary Disease and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 21 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jun 2023 · 7 months · monthly snapshot~Jun 2023 – ~Nov 2023 · 5 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: CompletedTerminated

  5. Jun 2023 — Nov 2023 [monthly]

    Completed PHASE2

Show 16 earlier versions
  1. Nov 2022 — Jun 2023 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  2. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  3. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  4. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  6. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  7. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  8. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  9. Apr 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  10. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  11. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  12. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  13. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  14. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  15. May 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

  16. Mar 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .